Skip to main content
OpenTrials
Completed

NCT Number: NCT01719614

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

The purpose of the study is to evaluate the effect of steady-state (constant concentration of medication in the blood) rilpivirine on pharmacokinetics (how a single dose of metformin is absorbed in the body, distributed within the body, and removed from the body) of a single dose of metformin, over time, in healthy adult participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Participants

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Overland Park, Kansas, United States

About this study

This is a phase I, open-label (all people know the identity of the intervention) and sequential study (study medication is given in a sequence) in healthy participants, to investigate the pharmacokinetic interaction between steady-state rilpivirine and a single dose of metformin. The study consists of 3 phases including, the screening phase (28 days before enrollment), treatment phase (19 days), and the follow-up phase (7 days after the last intake of study medication). All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15). The duration of the study is approximately 54 days. Safety evaluations including adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination (including skin examination) will be monitored throughout the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants should be healthy on the basis of physical examination, medical history, vital signs, electrocardiogram, the results of blood biochemistry and hematology tests and a urinalysis performed at screening
  • Participant must have a Body Mass Index of 18.5 to 30.0 kg/m2
  • Male participants should agree to protocol-defined use of effective contraception and women must be postmenopausal or surgically sterile
  • Female participants must have a negative pregnancy test at screening
  • Participants must be non-smoking for at least 3 months prior to screening

Exclusion criteria

  • A positive Human immunodeficiency virus (HIV)-1 or HIV-2 test and Hepatitis A, B or C infection at screening
  • Currently active clinically significant gastrointestinal, cardiovascular, neurologic, psychiatric, metabolic, endocrine, renal, hepatic, respiratory, inflammatory or infectious disease with any history of clinically significant skin disease
  • Any history of tuberculosis, ocular herpes, or uveitis
  • Have previously participated in more than one study with etravirine - TMC120 (dapivirine) and/or rilpivirine
  • Participants with abnormal laboratory values at screening

Treatment and study plan

metformin

Drug

Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.

Rilpivirine

Drug

Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.

Primary outcomes

  1. Maximum observed plasma analyte concentration (Cmax) of metformin

    Time frame: Day 1 and Day 15

  2. Actual sampling time to reach the maximum plasma analyte concentration (tmax) of metformin

    Time frame: Day 1 and Day 15

  3. Area under curve from time of administration up to the last time point with a measurable plasma analyte concentration after dosing (AUClast) of metformin

    Time frame: Day 1 and Day 15

  4. AUC extrapolated to infinity of metformin

    Time frame: Day 1 and Day 15

    AUC extrapolated to infinity, calculated as AUClast + Clast/apparent terminal elimination rate constant, where Clast is the last measurable plasma analyte concentration; extrapolations of more than 20 percent of the total AUC are reported as approximations.

  5. Apparent terminal elimination rate constant of metformin

    Time frame: Day 1 and Day 15

    Apparent terminal elimination rate constant will be estimated by linear regression using the terminal log-linear phase of the logarithmic transformed conentration versus time data.

  6. Apparent terminal elimination half-life of metformin

    Time frame: Day 1 and Day 15

Secondary outcomes

  1. Predose plasma analyte concentration (C0h) of rilpivirine

    Time frame: Day 12, Day 13, Day 14, Day 15, Day 17, Day 18

  2. Minimum observed plasma analyte concentration (Cmin) of rilpivirine

    Time frame: Day 15

  3. Maximum observed plasma analyte concentration (Cmax) of rilpivirine

    Time frame: Day 15

  4. Actual sampling time to reach the maximum plasma analyte concentration (tmax) of rilpivirine

    Time frame: Day 15

  5. Observed plasma analyte concentration at the end of the 24-hour dosing interval (C24h)

    Time frame: Day 15

  6. AUC from time of administration up to 24 hours after administration (AUC24h)

    Time frame: Day 15

  7. Average steady-state plasma concentration (Css,av)

    Time frame: Day 15

    Css,av is calculated by AUC dosing interval/dosing interval at steady-state

  8. Fluctuation index (FI)

    Time frame: Day 15

    FI, percentage fluctuation is variation between maximum and minimum plasma concentration at steady-state

  9. Number of participants with adverse events as a measure of safety and tolerability

    Time frame: Up to 54 Days

Sponsors and collaborators

Lead sponsor

Janssen R&D Ireland

Industry

Registry information

Official study title

A Phase I, Open-Label Study in Healthy Subjects to Explore the Potential for a Pharmacokinetic Interaction Between Steady-State Rilpivirine and a Single Dose Of Metformin

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Nov 1, 2012
Registry last updated
Mar 6, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.